Epizyme (EPZM) Stock Price Down 5.7%

Shares of Epizyme Inc (NASDAQ:EPZM) were down 5.7% on Monday . The company traded as low as $11.43 and last traded at $11.43. Approximately 387,377 shares changed hands during trading, a decline of 54% from the average daily volume of 848,872 shares. The stock had previously closed at $12.12.

A number of analysts have recently weighed in on EPZM shares. BidaskClub raised shares of Epizyme from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a report on Wednesday, February 27th. Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a report on Wednesday, February 27th. Oppenheimer cut their price target on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, February 27th. Finally, Cowen reaffirmed a “buy” rating and set a $18.00 price target on shares of Epizyme in a report on Tuesday, February 26th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.90.

The stock has a market capitalization of $1.05 billion, a PE ratio of -7.48 and a beta of 3.08. The company has a current ratio of 12.55, a quick ratio of 12.55 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.07. The company had revenue of $7.89 million for the quarter, compared to analyst estimates of $1.13 million. Equities research analysts expect that Epizyme Inc will post -1.98 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of EPZM. Primecap Management Co. CA raised its holdings in shares of Epizyme by 7.3% in the first quarter. Primecap Management Co. CA now owns 10,253,801 shares of the biopharmaceutical company’s stock valued at $127,045,000 after purchasing an additional 697,274 shares during the last quarter. Redmile Group LLC boosted its position in shares of Epizyme by 15.9% in the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock valued at $95,329,000 after acquiring an additional 1,056,742 shares during the period. BlackRock Inc. boosted its position in shares of Epizyme by 19.0% in the fourth quarter. BlackRock Inc. now owns 5,193,287 shares of the biopharmaceutical company’s stock valued at $31,990,000 after acquiring an additional 830,815 shares during the period. Vanguard Group Inc. boosted its position in shares of Epizyme by 1.9% in the third quarter. Vanguard Group Inc. now owns 4,570,139 shares of the biopharmaceutical company’s stock valued at $48,443,000 after acquiring an additional 84,726 shares during the period. Finally, Vanguard Group Inc boosted its position in shares of Epizyme by 1.9% in the third quarter. Vanguard Group Inc now owns 4,570,139 shares of the biopharmaceutical company’s stock valued at $48,443,000 after acquiring an additional 84,726 shares during the period. 74.44% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was originally posted by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://sundanceherald.com/2019/05/23/epizyme-epzm-stock-price-down-5-7.html.

About Epizyme (NASDAQ:EPZM)

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Featured Article: Sell-Side Analysts

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply